Clinical Trial Update: An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating the combination of Dalargin with Leitragin for severe and critical SARS-CoV-2 infections has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxemia
• Pneumonia
• Respiratory Insufficiency
• Respiratory Tract Infection
• Septic Shock

Drugs mentioned

• Dalargin (Dalargin)
• Leitragin (Leitragin)

Snippet

Sponsor: Burnasyan Federal Medical Biophysical Center | Conditions: Acute Respiratory Tract Infection, Acute Respiratory Insufficiency | Phase 3 | Status: COMPLETED